65,437 trials
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 9.6; 75.3 percentage of participants — p=< 0.001
Schizophrenia
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 56.4; 65.2; 60.5 percentage of participants
Pain
Primary: Post-operative Pain — 15; -31 Scores on a scale — p=0.04
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events (AEs) — 354; 337; 108; 799 participants
Tachycardia, Ventricular
Primary: Percentage of Participants Free of Type I Complications at 180 Days. — 99.0 percentage of participants
Chronic Stable Plaque Psoriasis
Primary: PASI 75 Response Rate at Week 12 - GP2015 Etanercept vs. Enbrel ® Etanercept — 73.4; 75.7 % of patients achieving PASI75 response
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen® — 7.5; 7.5 percentage (%) of total haemoglobin
Obstructive Sleep Apnea
Primary: Apnoea Hypopnoea Index (AHI) — 0.96; 0.91 events/hour
Breast Cancer
Primary: Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively. — 13; 8; 33; 54 participants
Actinic Keratosis
Primary: Adherence to Carac® in Subjects With Moderate to Severe Actinic Keratosis. — 86 percentage of prescribed doses
Myocardial Blood Flow Reserve
Primary: Measure Quantitated Myocardial Perfusion Reserve After a 4 Minute Delay in Lexiscan (Regadenoson) — 2.57 Ratio
Pulmonary Disease, Chronic Obstructive
Primary: Maximal Change in Forced Expiratory Volume in One Second (FEV1) From Baseline (Pre-dose on Day 1) in Combination With Short Acting Bronchodialator (Salbutamol or…
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at Week 12 — 2.7; 11.3; 16.7; 15.5 percentage of participants — p=0.0213
Gastroesophageal Reflux Disease · Systemic Sclerosis · Scleroderma
Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)
Respiratory Failure
Primary: Level of Activity of Daily Life — 25.2; 32.0 units on a scale — p=0.652